| Description |
Recombinant Biotinylated Human HPV16 E7(HLA-A*02:01) Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and YMLDLQPET peptide. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
P04439-1(HLA-A*02:01) &P61769(B2M) &YMLDLQPET peptide |
| Target Symbol |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer |
| Synonyms |
HPV16; E7; MHC; |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
C-His-Avi |
| Expression Range |
Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide |
| Mol. Weight |
The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. |
